## Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

ALEXION I Form 4 February 12	PHARMACEUT	ICALS IN	IC								
Check th if no lon, subject to Section 2 Form 5 obligation may con See Instr 1(b).	<b>1 4</b> UNITED UNITED UNITED STATEN STATEN Section 17	Wa F CHAN Section 1 Public U	shington IGES IN SECUF 6(a) of th	, D.C. 20 BENEF XITIES ne Securi ding Con	<b>)549</b> TCIA ties E	LOWN Exchange y Act of	OMMISSION NERSHIP OF e Act of 1934, 1935 or Sectior 0	OMB APPROVAL OMB 3235-03 Number: January Expires: 20 Estimated average burden hours per response			
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Moriarty John B			2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) ALEXION PHARMAC KNOTTER	3. Date of Earliest Transaction (Month/Day/Year) 02/10/2015					Director 10% Owner X_ Officer (give title Other (specify below) EVP & General Counsel					
CHESHIRE	4. If Amendment, Date Original Filed(Month/Day/Year)					<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> <li>Person</li> </ul>					
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Secur	ities Acqu	uired, Disposed of	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Data (Month/Day/Year)		ned 1 Date, if	3. Transactio Code (Instr. 8)	4. Securi on(A) or D (Instr. 3, Amount	ties Ad isposed	cquired d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, par value \$.0001 per share	02/10/2015			S	1,490 (1)	D	\$ 171.15	26,777	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

## Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

## number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	rivative Conversion (Month/Day/Year curity or Exercise		Executio any	med on Date, if Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
					Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Reporting Owners												
Report	ing Owner Na	ame / Address			Relat	Relationships						
			Director	10% Own	ner Office	er		Other				
352 KNO					EVI	P & Gene	eral Counsel	l				
Signa	tures											
•		attorney-in-Fact fo	or John F	3.	02	2/12/2015	;					
	<u>**</u> Signatu	are of Reporting Person				Date						
Expla	nation	of Respo	inses	31								
* 1641 6	C : 6:1 1.1					()						

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.